SITC 2022 – Posters will be presented in person at the Boston Convention & Exhibition Center on Thursday, November 10th, 2022
Society for the Immunotherapy of Cancer 2022 Annual Meeting, November 8 – 12, Boston, MA,...
09Nov
04Oct
Dr. Philip M. Arlen gives presentation on recent NEO-201 clinical development at Biomarkers & Immuno US, 4th Annual Advances in Immuno-Oncology USA Congress, San Diego, CA, October 4, 2022
Dr. Philip M. Arlen gives presentation “Preclinical/Clinical Development of a Neo-Epitope Targeted Monoclonal Antibody for...
05Jun
Precision Biologics, Inc. and National Cancer Institute Collaborators Deliver Poster Presentation at the ASCO Annual Meeting June 5, 2022
Precision Biologics, Inc. and our collaborators at the NCI deliver a poster presentation at the...
07Apr
Dr. Philip M. Arlen provides perspective on the role of biomarkers for cancer immunotherapy at Oxford Global’s 2021 Biomarkers UK Conference
Dr. Philip M. Arlen provides perspective on the role of biomarkers for cancer immunotherapy at...
22Mar
Precision Biologics, Inc. Announces Issuance of U.S. Patent: “MONOCLONAL ANTIBODY NEO-201 FOR THE TREATMENT OF HUMAN CARCINOMAS”
Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announces that the U.S....
09Mar
Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics, San Diego, March 9, 2022
Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics 2022, San...
28Jan
Precision Biologics, Inc. appoints Dr. Joyson Karakunnel to the Board of Directors
Dr. Joyson Karakunnel joins the Board of Directors of Precision Biologics, Inc. as its newest...
08Nov
Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, November 8, 2021, Manchester, UK
Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, Day 1 – November...
29Oct
Phase II Clinical Trial NEO-201 in Combination with Pembrolizumab Detailed Study Information
The Phase 2 Clinical Trial with a safety lead in, combining Precision Biologics monoclonal antibody...
28Oct
Precision Biologics to Deliver two Oral Presentations on our Clinical and Scientific Programs at 6th Annual Neoantigen Based Therapies Summit, October 26-28th, Digital Event
Dr Massimo Fantini, Director of Research is Presenting the following Talk entitled : “Stability Tests...